title: Sequential immunosuppression: three years' experience in 240 cadaveric renal transplants.
authors.affiliation: Transplantation Services, Washington Hospital Center, Washington, DC 20010.
authors.forename: J A
authors.initials: JA
authors.lastname: Light
authors.forename: J
authors.initials: J
authors.lastname: Jonsson
authors.forename: N
authors.initials: N
authors.lastname: Khawand
authors.forename: A
authors.initials: A
authors.lastname: Ali
authors.forename: A
authors.initials: A
authors.lastname: Aquino
authors.forename: C B
authors.initials: CB
authors.lastname: Currier
authors.forename: J
authors.initials: J
authors.lastname: Romolo
authors.forename: J
authors.initials: J
authors.lastname: Gonzalez
authors.forename: S
authors.initials: S
authors.lastname: Korb
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002102:Cadaver; D003141:Communicable Diseases / Q000150:complications; D004306:Dose-Response Relationship, Immunologic; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000379:methods*; D016853:Muromonab-CD3; D016019:Survival Analysis
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D016853:Muromonab-CD3